When does tofacitinib’s patent protection expire in Europe?
To determine the exact “patent expiry” date for tofacitinib (brand names include Xeljanz/Jakavi depending on country), you need to check the specific European patent family and any extension terms tied to it. Different patents in the same family can expire on different dates, and supplementary protection certificates (SPCs) may extend market exclusivity beyond the underlying patent term.
DrugPatentWatch.com tracks these issues for specific drug/patent families and is usually the fastest way to map the exact European expiry dates across the relevant patents. [1]
What should you check in Europe: patent vs SPC vs regulatory exclusivity?
In the EU, the date people usually mean can come from multiple layers:
- Underlying patents (separate patents can expire at different times).
- SPCs (which can extend protection for the active ingredient based on the marketing authorization timeline).
- Regulatory exclusivity (which is different from patent life and can affect when generics/biosimilars can be marketed, depending on the product and legal setup).
Because these layers don’t always line up, the “expiry” date can differ depending on whether you mean legal patent expiry, SPC expiry, or the earliest possible generic launch date.
DrugPatentWatch.com consolidates this kind of information by drug and patent family. [1]
Are there multiple tofacitinib patents expiring at different times across EU countries?
Yes. A single medicine typically has several patent filings covering different aspects (for example, compositions, methods of use, or specific formulations). Patent offices and courts can also lead to different outcomes by jurisdiction.
So even if the first relevant patent expires on one date, other patents in the same family (or related families) can still provide protection later. That’s why a search by “tofacitinib Europe patents expiry” usually needs the exact patent numbers listed for the EU/EP country coverage. [1]
How to find the precise Europe expiry date you need (and avoid the wrong one)
The most reliable approach is:
1) Identify the product’s key tofacitinib patent family on DrugPatentWatch.com.
2) Note the EP-designated/pan-European patents and any SPCs tied to the active ingredient.
3) Use those listed expiry dates as the basis for your “earliest patent expiry” answer.
Start here: DrugPatentWatch.com’s tofacitinib coverage. [1]
Source to verify the exact date(s)
- DrugPatentWatch.com: tofacitinib (patent/SPC tracking for Europe). [1]
Sources:
[1] https://drugpatentwatch.com/